MOUNTAIN VIEW, Calif., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Heartflow, Inc. (Heartflow) (Nasdaq: HTFL), a leader in AI technology for coronary artery disease (CAD), today announced the closing of its upsized initial public offering of 19,166,667 shares of its common stock at a public offering price of $19 per share, which includes 2,500,000 shares of common stock issued upon the exercise in full by the underwriters of their option to purchase additional shares. All of the shares of common stock were offered by Heartflow. The total gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Heartflow, were approximately $364.2 million. Heartflowâs common stock began trading on the Nasdaq Global Select Market on August 8, 2025 under the ticker symbol âHTFL.â
Related Questions
What is the expected dilution impact on existing shareholders and how will it affect earnings per share (EPS) forecasts?
How does the $364.2âŻmillion capital raise position Heartflow for future R&D and commercial rollout of its AI CAD platform?
What is the lockâup period for insiders and early investors, and when might additional share sales be permitted?
How might the full exercise of the underwriters' option (2.5âŻmillion extra shares) affect supply and shortâterm liquidity in the market?
What is the anticipated trading volume and float on the Nasdaq, and how could that impact price volatility?
Are there any regulatory or reimbursement risks that could impact Heartflow's commercial adoption timeline?
What is the sentiment among institutional investors and are there any notable preâIPO allocations that could influence postâIPO support?
How will the $19 per share IPO price compare to the current market valuation and affect postâIPO price dynamics?
How does Heartflow's valuation multiples (e.g., EV/Revenue, P/E) compare to other AIâenabled cardiovascular technology peers?
What are the projected revenue growth trajectories for Heartflow's AI solutions in the next 12â24 months?